Antiphospholipidantibodies in systemic lupus erythematosus patients
Authors:
Z. Fojtík 1; M. Beránek 2; Z. Kořístek 1; M. Klabusay 1; A. Buliková 3
Authors‘ workplace:
Interní hematoonkologická klinika, Fakultní nemocnice Brno Bohunice, 2Centrum biostatistiky a analýz Lékařské a Přírodovědecké fakulty MU, 3Oddělení klinické hematologie, Brno
1
Published in:
Čes. Revmatol., , 2003, No. 4, p. 169-173.
Category:
Overview
Different levels of coagulation cascade may be variously altered by antiphospholipid antibodies(APA). The aPL may cause different clinical symptoms, typically thrombosis, recurrent miscarriagesand thrombocytopenia. Aim: to analyse retrospectively occurrence of lupus anticoagulant (LA) andAPA (mixture of phospholipids – cardiolipin, phosphatidic acid and phosphatidylserin in thecommercial set) in systemic lupus erythematosus (SLE) patients and to correlate these parameterswith the history of thrombotic events. Material and methods: A group of 46 patients who fulfilledACR criteria for SLE was evaluated. Nonspecific parameters of inflammation, autoantibodies (ANA,anti-ENA, anti-dsDNA,anti-Ro, anti-La, anti-Sm, anti-snRNP),lupus anticoagulant andantiphospholipidantibodies – cardiolipin, phosphatidic acid and phosphatidylserin in commercial set (APA test)were followed. A history of thrombotic events was evaluated. Results: In this group there were 13LA positive, 33 LA negative, 18 APA positive, and 28 APA negative patients. Forty thrombotic eventswere detected. Venous thrombosis was detected in 62% in a group of LA positive and in 18% in LAnegative patients (p
Key words:
Labels
Dermatology & STDs Paediatric rheumatology RheumatologyArticle was published in
Czech Rheumatology
2003 Issue 4
Most read in this issue
- Surgical treatment of foot and ankle deformities in rheumatoidarthritis patients
- Antiphospholipidantibodies in systemic lupus erythematosus patients
- Longitudinal follow-up of knee osteoarthritis progression using MR imaging.Outcomes of two years study
- Observational study in osteoarthritis and rheumatoid arthritis patients usingcelecoxib